General
Preferred name
pitavastatin
Synonyms
PITAVASTATIN CALCIUM ()
Pitavastatin D4 ()
NK-104 D4 ()
NK-104 hemicalcium ()
Pitavastatin hemicalcium ()
P-872441 ()
NK104 ()
NK 104 ()
NK-104 ()
Pitavastatin calcium salt ()
Itavastatin calcium ()
Livalo ()
Pitavastatine ()
NSC-760423 ()
Pitavastatin component of k-924 pivastatin ()
Pitavastatina ()
Nikita ()
PITAVASTATIN SODIUM ()
Zypitamag ()
PITAVASTATIN MAGNESIUM ()
Pitavastatin (calcium salt) ()
P&D ID
PD009185
CAS
147526-32-7
147511-69-1
121659-03-8
Tags
available
drug
Approved by
PMDA
FDA
First approval
2017
2009
Drug indication
Abnormal circulating lipid concentration
Dyslipidemia
Primary hyperlipidemia and mixed dyslipidemia
Cardiovascular disease
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
65
DESCRIPTION
Pitavastatin is a statin drug.
(GtoPdb)
ABSORPTION
Bioavailability = 51%;; Time to peak, plasma = 1 hour;; Pitavastatin was absorbed in the small intestine but very little in the colon. Cmax decreases by 43% if pitavastatin is taken with a fatty meal but there are no significant changes to AUC or baseline LDL levels compared to fasting state. The Cmax and AUC of pitavastatin did not differ following evening or morning drug administration.
METABOLISM
Pitavastatin is mainly metabolized by liver. It undergoes glucuronidation by uridine 5-diphosphate glucuronosyl transferases (UGT1A3 and UGT2B7) to form the major circulating metabolite, pitavastatin lactone. ; ; The cytochrome P450 system has little involvement with the metabolism of pitavastatin. There is some metabolism by CYP2C9 and to a lesser extent, CYP2C8. Studies suggest that concomitant therapy with drugs that are involved with the cytochrome P450 system will not effect the pharmacokinetics of pitavastatin.
DESCRIPTION
Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects[1][2][3][8].
PRICE
41
DESCRIPTION
Potent and selective ALK1 and ALK2 inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
HMG-CoA reductase inhibitor
(Tocriscreen Plus)
DESCRIPTION
Pitavastatin calcium (NK-104) is a potent inhibitor of HMG-CoA reductase (Ki: 1.7 nM). It lowers both total cholesterol and low-density lipoprotein cholesterol in animals and humans. Metabolism of pitavastatin by the cytochrome P450 system is minimal, reducing the risk of drug-drug interactions.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Pitavastatin (NK-104) is a potent inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) reductase, effectively inhibiting cholesterol synthesis from acetic acid in HepG2 cells with an IC50 of 5.8 nM. It also induces hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptors and exhibits therapeutic activities such as anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective, and reno-protective effects.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
23
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
Tocris Bioactive Compound Library
Tocriscreen Plus
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
180
Molecular Weight
421.17
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
8
Ring Count
4
Aromatic Ring Count
3
cLogP
4.52
TPSA
90.65
Fraction CSP3
0.28
Chiral centers
2.0
Largest ring
6.0
QED
0.5
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target Type
Enzymes
Target
Autophagy
HMG-CoA Reductase (HMGCR)
Mitophagy
HMGCR
cholesterol esters
Pathway
Metabolic Enzyme/Protease
Apoptosis
Metabolism
Primary Target
HMG-CoA Reductase
MOA
Inhibitor
SPP1 (Osteopontin) Expression Inhibitors
APOA1 Expression Enhancers
HMG-CoA Reductase Inhibitors
HMGCR inhibitor
Member status
virtual
Indication
hyperlipidemia
Source data

